Medline’s Surgical Glove Case: Duty Relief, a Tribunal Win and a Reversal

Medline Canada’s surgical-glove dispute shows how an importer can challenge duties by looking beyond a product’s ordinary tariff classification. The company initially won additional duty relief through Chapter 99 of the Customs Tariff. That ruling was later overturned. Understanding the case means separating it from the temporary COVID-19 remission program.

What pandemic remission actually provided

Canada’s Certain Goods Remission Order (COVID-19) temporarily relieved customs duties on specified medical supplies. Surgical rubber gloves under tariff item 4015.11.00 appeared among the eligible goods. Relief was available subject to the order’s conditions; it did not permanently change the gloves’ classification. CBSA Customs Notice 20-19

CBSA subsequently confirmed that the program generally covered eligible imports from May 5, 2020 through May 6, 2022. The repeal took effect on May 7, 2022, with an exception for qualifying goods already bound for Canada under a carrier’s control before that date. This was temporary relief with eligibility dates and supporting-document requirements. CBSA Customs Notice 22-08

How Medline initially won its classification appeal

Medline’s appeals concerned sterile rubber surgical gloves imported between November 2015 and March 2018. Between November 2019 and July 2021, it submitted 395 refund requests seeking relief under tariff item 9977.00.00. The imports—and the start of the refund effort—predated the pandemic remission program.

Medline accepted the gloves’ ordinary classification under 4015.11.00. It argued that they also qualified for Chapter 99 relief because of their relationship with surgical instruments such as scalpels. Its case focused on whether the gloves were physically connected and functionally joined to those instruments.

The Canadian International Trade Tribunal accepted that argument. It considered the gloves’ contact with scalpels, improved grip and tactile feedback, and infection protection. On January 29, 2024, it allowed the appeals and found the goods eligible for additional relief under 9977.00.00. A corrigendum followed on March 18, 2025.

The published decision establishes a Chapter 99 classification claim concerning older imports. It does not establish that pandemic remission secured this result. CITT decision, AP-2022-004 and AP-2022-017

Why the result changed on appeal

On April 16, 2026, the Federal Court of Appeal set aside the Tribunal’s decision in Canada (Attorney General) v. Medline Canada Corporation, 2026 FCA 74. It declared that the gloves in issue were not classifiable under 9977.00.00.

The Court held that using gloves together with a scalpel did not satisfy the provision’s requirements. The surgeon’s hand maintained the connection; the gloves were not incorporated into the instrument. It also distinguished benefits to the surgeon from improvements to the scalpel itself.

That reversal changes the commercial lesson: the Tribunal’s initial success cannot be presented as continuing entitlement to duty-free treatment under this provision. Federal Court of Appeal judgment, particularly paragraphs 73–75 and 87

What importers should take from the case

For an importer reviewing medical-product costs, Vectura’s practical starting point is to identify the precise basis for any proposed savings:

• Check the route to relief. A remission order, a preferential tariff rate and Chapter 99 relief each have their own requirements.
• Match the evidence to the rule. Product specifications, actual use, origin and import dates can determine which provisions deserve review.
• Check subsequent decisions. A favourable tribunal ruling may change on appeal; an older case summary is not enough to support a current claim.

The tariff numbers discussed here describe the litigation. Current shipments require a review of the applicable tariff and the particular goods. Vectura Customs can help assess that position before an importer claims relief or pursues a refund.